INmune Bio Q2 net loss narrows on lower impairment charges

Inmune Bio

06/08/2026 21:09

Overview
US biotechnology firm's Q2 net loss narrowed sharply from prior year
Company reported no revenue for the quarter
Q2 results benefited from Australian R&D tax rebate and lower impairment charges

Outlook
Company plans UK MAA submission for Ebstrocel by end of Q3 or early Q4 2026
INmune Bio expects EU EMA and US FDA submissions for Ebstrocel in Q1 2027
Company expects XPro Phase 2b/3 protocol submission to FDA in Q4 2026

Result Drivers
R&D TAX REBATE - Co said recognition of Australian R&D tax rebate reduced research and development expenses in Q2
NO IMPAIRMENT CHARGES - Co said prior-year period included $16.5 mln impairment charge that did not recur in Q2 2026

Company press release: ID:nGNX705CkW

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$1.27 mln
 
Q2 Loss Per Basic Share
 
$0.05
 
Q2 Operating Expenses
 
$1.48 mln
 
     

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for INmune Bio Inc is $7.50, about 294.7% above its August 5 closing price of $1.90

Reuters Recommended Reads
Aug 6 - ALX Oncology Q2 net loss narrows on lower R&D costs
Aug 6 - Prime Medicine Q2 net loss narrows on lower expenses
Aug 5 - Emergent BioSolutions swings to Q2 loss on impairment charge; to cut jobs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)